Tianeptine

Last updated

Tianeptine
Tianeptine2DACS.svg
Tianeptine structure.png
Clinical data
Trade names Stablon, Coaxil, Tatinol
Other namesTia; [1] ZaZa; [2] S-1574; [3] [4] [5] JNJ-39823277; TPI-1062 [6]
AHFS/Drugs.com International Drug Names
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 99% [9] [10]
Protein binding 95% [10]
Metabolism Hepatic [10] by β-oxidation [11]
Elimination half-life 2.5–3 hours [9] [10]
4–9 hours (elderly) [10] [12]
Excretion Urine: 65% [9]
Feces: 15% [10]
Identifiers
  • 7-[(3-Chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.131.750 100.069.844, 100.131.750 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C21H25ClN2O4S
Molar mass 436.95 g·mol−1
3D model (JSmol)
  • Clc1cc2c(cc1)C(c3c(N(C)S2(=O)=O)cccc3)NCCCCCCC(=O)O
  • InChI=1S/C21H24ClN2NaO4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26) Yes check.svgY
  • Key:JICJBGPOMZQUBB-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome. [3] [4] [5]

Contents

Tianeptine has antidepressant and anxiolytic effects [13] with a relative lack of sedative, anticholinergic, and cardiovascular side effects. [10] [14] It has been found to act as an atypical agonist of the μ-opioid receptor with clinically negligible effects on the δ- and κ-opioid receptors. [15] [16] [17] This may explain part of its antidepressant and anxiolytic effects; however, it is thought that tianeptine also modulates glutamate receptors, and this may also explain tianeptine's antidepressant/anxiolytic effects.

Tianeptine was discovered and patented by the French Society of Medical Research in the 1960s. Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in a number of other European countries under the trade name Coaxil as well as in Asia (including Singapore) and Latin America as Stablon and Tatinol but it is not available in Australia, Canada, New Zealand, or the United Kingdom. [18] [19] In the US, it is an unregulated drug sold under several names and some of these products have been found to be adulterated with other recreational drugs. [20]

Medical uses

Depression and anxiety

Tianeptine shows efficacy against serious depressive episodes (major depression), comparable to amitriptyline, imipramine and fluoxetine, but with significantly fewer side effects. [18] It was shown to be more effective than maprotiline in a group of people with co-existing depression and anxiety. [10] Tianeptine also displays significant anxiolytic properties and is useful in treating a spectrum of anxiety disorders including panic disorder, as evidenced by a study in which those administered 35% CO2 gas (carbogen) on paroxetine or tianeptine therapy showed equivalent panic-blocking effects. [21] Like many antidepressants (including bupropion, the selective serotonin reuptake inhibitors, the serotonin-norepinephrine reuptake inhibitors, moclobemide and numerous others) it may also have a beneficial effect on cognition in people with depression-induced cognitive dysfunction. [22] A 2005 study in Egypt showed tianeptine to be effective in men with depression and erectile dysfunction. [23]

Tianeptine has been found to be effective in depression, in people with Parkinson's disease, [24] and with post-traumatic stress disorder [25] for which it was as safe and effective as fluoxetine and moclobemide. [26]

Other uses

A clinical trial comparing its efficacy and tolerability with amitriptyline in the treatment of irritable bowel syndrome showed that tianeptine was at least as effective as amitriptyline and produced fewer prominent adverse effects, such as dry mouth and constipation. [27]

Tianeptine has been reported to be very effective for asthma. In August 1998, Dr. Fuad Lechin and colleagues at the Central University of Venezuela Institute of Experimental Medicine in Caracas published the results of a 52-week randomized controlled trial of asthmatic children; the children in the groups who received tianeptine had a sharp decrease in clinical rating and increased lung function. [28] Two years earlier, they had found a close, positive association between free serotonin in plasma and severity of asthma in symptomatic persons. [28] As tianeptine was the only agent known to both reduce free serotonin in plasma and enhance uptake in platelets, they decided to use it to see if reducing free serotonin levels in plasma would help. [28] By November 2004, there had been two double-blind placebo-controlled crossover trials and an under-25,000 person open-label study lasting over seven years, both showing effectiveness. [28]

Tianeptine also has anticonvulsant and analgesic effects, [29] and a clinical trial in Spain that ended in January 2007 has shown that tianeptine is effective in treating pain due to fibromyalgia. [30] Tianeptine has been shown to have efficacy with minimal side effects in the treatment of attention-deficit hyperactivity disorder. [31]

Contraindications

Known contraindications include the following: [32]

Side effects

Compared to other tricyclic antidepressants, it produces significantly fewer cardiovascular, anticholinergic (like dry mouth or constipation), sedative and appetite-stimulating effects. [14] [18] A recent review found that it was amongst the antidepressants most prone to causing hepatotoxicity (liver damage), although the evidence to support this concern was of limited quality. [34] [35] Unlike other tricyclic antidepressants, tianeptine does not affect heart function. [36] μ-Opioid receptor agonists can sometimes induce euphoria, as does tianeptine, occasionally, at high doses, well above the normal therapeutic range. Tianeptine can also cause severe withdrawal symptoms after prolonged use at high doses which should prompt extreme caution. [37] [38]

By frequency

Sources: [10] [14] [39]

Common (>1% frequency)
  • Headache (up to 18%)
  • Dizziness (up to 10%)
  • Insomnia/nightmares (up to 20%)
  • Drowsiness (up to 10%)
  • Dry mouth (up to 20%)
  • Constipation (up to 15%)
  • Nausea
  • Abdominal pain
  • Weight gain (~3%)
  • Agitation
  • Anxiety/irritability
Uncommon (0.1–1% frequency)
Rare (<0.1% frequency)

Pharmacology

Pharmacodynamics

Tianeptine [41]
SiteKi (nM)SpeciesRef
MOR Tooltip μ-Opioid receptor383–768 (Ki)
194 (EC50 Tooltip Half-maximal effective concentration)		Human [15] [41]
[15]
DOR Tooltip δ-Opioid receptor>10,000 (Ki)
37,400 (EC50)		Human [15] [41]
[15]
KOR Tooltip κ-Opioid receptor>10,000 (Ki)
100,000 (EC50)		Human [15] [41]
[15]
SERT Tooltip Serotonin transporter>10,000Human [41]
NET Tooltip Norepinephrine transporter>10,000Human [41]
DAT Tooltip Dopamine transporter>10,000Human [41]
5-HT1A >10,000Human [41]
5-HT1B >10,000Human [41]
5-HT1D >10,000Human [41]
5-HT1E >10,000Human [41]
5-HT2A >10,000Human [41]
5-HT2B >10,000Human [41]
5-HT2C >10,000Human [41]
5-HT3 >10,000Human [41]
5-HT5A >10,000Human [41]
5-HT6 >10,000Human [41]
5-HT7 >10,000Human [41]
α1A >10,000Human [41]
α1B >10,000Human [41]
α2A >10,000Human [41]
α2B >10,000Human [41]
α2C >10,000Human [41]
β1 >10,000Human [41]
β2 >10,000Human [41]
D1 >10,000Human [41]
D2 >10,000Human [41]
D3 >10,000Human [41]
D4 >10,000Human [41]
D5 >10,000Human [41]
H1 >10,000Human [41]
H2 >10,000Human [41]
H3 >10,000Human [41]
H4 >10,000Human [41]
mACh Tooltip Muscarinic acetylcholine receptor>10,000Human [41]
σ1 >10,000Guinea pig [41]
σ2 >10,000Rat [41]
I1 >10,000Human [41]
A1 >10,000 (EC50)Human [15]
VDCC Tooltip Voltage-dependent calcium channel>10,000Human [41]
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug interacts with the site.

Atypical μ-opioid receptor agonist

In 2014, tianeptine was found to be a μ-opioid receptor (MOR) full agonist using human proteins. [15] It was also found to act as a full agonist of the δ-opioid receptor (DOR), although with approximately 200-fold lower potency. [15] The same researchers subsequently found that the MOR is required for the acute and chronic antidepressant-like behavioral effects of tianeptine in mice and that its primary metabolite had similar activity as a MOR agonist but with a much longer elimination half-life. [42] Moreover, in mice, although tianeptine produced other opioid-like behavioral effects such as analgesia and reward, it did not result in tolerance or withdrawal. [42] The authors suggested that tianeptine may be acting as a biased agonist of the MOR and that this may be responsible for its atypical profile as a MOR agonist. [42] However, there are reports that suggest that withdrawal effects resembling those of other typical opioid drugs (including but not limited to depression, insomnia, and cold/flu-like symptoms) do manifest following prolonged use at dosages far beyond the medical range. [43] [44] In addition to its therapeutic effects, activation of the MOR is likely to also be responsible for the abuse potential of tianeptine at high doses that are well above the normal therapeutic range and efficacy threshold.

In rats, when co-administered with morphine, tianeptine prevents morphine-induced respiratory depression without impairing analgesia. [45] In humans, however, tianeptine was found to increase respiratory depression when administered in conjunction with the potent opioid remifentanil. [46]

Glutamatergic, neurotrophic, and neuroplastic modulation

Research suggests that tianeptine produces its antidepressant effects through indirect alteration and inhibition of glutamate receptor activity (i.e., AMPA receptors and NMDA receptors) and release of BDNF Tooltip brain-derived neurotrophic factor, in turn affecting neural plasticity. [47] [48] [49] [50] [14] [18] Some researchers hypothesize that tianeptine has a protective effect against stress induced neuronal remodeling. [47] [14] There is also action on the NMDA and AMPA receptors. [47] [14] In animal models, tianeptine inhibits the pathological stress-induced changes in glutamatergic neurotransmission in the amygdala and hippocampus. It may also facilitate signal transduction at the CA3 commissural associational synapse by altering the phosphorylation state of glutamate receptors. With the discovery of the rapid and novel antidepressant effects of drugs such as ketamine, many believe the efficacy of antidepressants is related to promotion of synaptic plasticity. This may be achieved by regulating the excitatory amino acid systems that are responsible for changes in the strength of synaptic connections as well as enhancing BDNF expression, although these findings are based largely on preclinical studies. [18]

Serotonin reuptake enhancer

Tianeptine is no longer labelled a selective serotonin reuptake enhancer (SSRE) antidepressant. [47] [48] [49] [50] [14] [18] Tianeptine had been found to bind to the same allosteric site on the serotonin transporter (SERT) as conventional TCAs. [51] However, whereas conventional TCAs inhibit serotonin reuptake by the SERT, tianeptine appeared to enhance it. [51] This seems to be because of the unique C3 amino heptanoic acid side chain of tianeptine, which, in contrast to other TCAs, is thought to lock the SERT in a conformation that increases affinity for and reuptake (Vmax) of serotonin. [51] As such, tianeptine was thought to act a positive allosteric modulator of the SERT, or as a "serotonin reuptake enhancer". [51]

Although tianeptine was originally found to have no effect in vitro on monoamine reuptake, release, or receptor binding, upon acute and repeated administration, tianeptine decreased the extracellular levels of serotonin in rat brain without a decrease in serotonin release, leading to a theory of tianeptine enhancing serotonin reuptake. [52] The (−)-enantiomer is more active in this sense than the (+)-enantiomer. [53] However, more recent studies found that long-term administration of tianeptine does not elicit any marked alterations (neither increases nor decreases) in extracellular levels of serotonin in rats. [47] However, coadministration of tianeptine and the selective serotonin reuptake inhibitor fluoxetine inhibited the effect of tianeptine on long-term potentiation in hippocampal CA1 area. This is considered an argument for the opposite effects of tianeptine and fluoxetine on serotonin uptake, [14] although it has been shown that fluoxetine can be partially substituted for tianeptine in animal studies. [54] In any case, the collective research suggests that direct modulation of the serotonin system is unlikely to be the mechanism of action underlying the antidepressant effects of tianeptine. [51]

Other actions

Tianeptine modestly enhances the mesolimbic release of dopamine [55] and potentiates CNS D2 and D3 receptors. [56] Tianeptine has no affinity for the dopamine transporter or the dopamine receptors. [47] CREB-TF (CREB, cAMP response element-binding protein) [57] is a cellular transcription factor. It binds to certain DNA sequences called cAMP response elements (CRE), thereby increasing or decreasing the transcription of the genes. [58] CREB has a well-documented role in neuronal plasticity and long-term memory formation in the brain. Cocaine- and amphetamine-regulated transcript, also known as CART, is a neuropeptide protein that in humans is encoded by the CARTPT gene. [59] [60] CART appears to have roles in reward, feeding, stress, [61] and it has the functional properties of an endogenous psychostimulant. [62] Taking into account that CART production is upregulated by CREB, [63] it could be hypothesized that due to tianeptine's central role in BDNF and neuronal plasticity, this CREB may be the transcription cascade through which this drug enhances mesolimbic release of dopamine.

Research indicates possible anticonvulsant (anti-seizure) and analgesic (painkilling) activity of tianeptine via downstream modulation of adenosine A1 receptors (as the effects could be experimentally blocked by antagonists of this receptor). [29] Tianpetine is also weak histone deacetylase inhibitor and analogs with increased potency and selectivity are developed. [64]

Pharmacokinetics

The bioavailability of tianeptine is approximately 99%. [9] [10] Its plasma protein binding is about 95%. [10] The metabolism of tianeptine is hepatic, via β-oxidation. [10] CYP enzymes are not involved, which limits the potential for drug-drug interactions. [10] Maximal concentration is reached in about an hour and the elimination half-life is 2.5 to 3 hours. [9] [10] The elimination half-life has been found to be increased to 4 to 9 hours in the elderly. [12] Tianeptine is usually packaged as a sodium salt but can also be found as tianeptine sulfate, a slower-releasing formulation patented by Janssen in 2012. [65] In 2022 Tonix Pharmaceuticals received permission from the US FDA to conduct phase II clinical trials on tianeptine hemioxalate extended-release tablets designed for once-daily use. [66] The project was discontinued in late 2023 because of disappointing results in clinical trials.

Tianeptine has two active metabolites, MC5 (a pentanoic acid derivative of the parent compound) and MC3 (a propionic acid derivative). [67] [10] MC5 has a longer elimination half-life [42] of approximately 7.6 hours, and takes about a week to reach steady-state concentration under daily-dosing. MC5 is a mu-opioid agonist but not delta-opioid agonist, with EC50 at the mu-opioid receptor of 0.545 μM (vs 0.194 μM for tianeptine). [42] MC3 is a very weak mu-opioid agonist, with an EC50 of 16 μM. [42] Tianeptine is excreted 65% in the urine and 15% in feces. [9] [10]

Chemistry

In terms of chemical structure, it is similar to tricyclic antidepressants (TCAs), but it has significantly different pharmacology and important structural differences, so it is not usually grouped with them.

Analogues

Although several related compounds are disclosed in the original patent, [68] no activity data are provided and it was unclear whether these share tianeptine's unique pharmacological effects. More recent structure-activity relationship studies have since been conducted, providing some further insight on μ-opioid, δ-opioid, and pharmacokinetic activity. [69] [70] [71] [72] [73] Derivatives where the aromatic chlorine substituent is replaced by bromine, iodine or methylthio, and/or the heptanoic acid tail is varied in length or replaced with other groups such as 3-methoxypropyl, show similar or increased opioid receptor activity relative to tianeptine itself. [74] [75] [76] Amineptine, the most closely related drug to have been widely studied, is a dopamine reuptake inhibitor with no significant effect on serotonin levels, nor opioid agonist activity. Tianeptinaline, analog of tianeptine, is a notable class I HDAC inhbitor. [64]

Society and culture

Stablon box and blister pack. StablonBox.jpg
Stablon box and blister pack.

Approval and brand names

Brand names include:

Development

Under the code names JNJ-39823277 and TPI-1062, tianeptine was previously under development for the treatment of major depressive disorder in the United States and Belgium. [6] Phase I clinical trials were completed in Belgium and the United States in May and June 2009, respectively. [6] For unclear reasons development of tianeptine was discontinued in both countries in January 2012. [6] In October 2023, Tonix Pharmaceuticals announced that it had discontinued its development of tianeptine as a monotherapy for major depressive disorder after disappointing phase-2 clinical trial results. [77] An ongoing clinical trial, sponsored by the New York Psychiatric Institute, is examining tianeptine's use in treatment-resistant depression. [78]

U.S. National Poison Data System data on tianeptine showed a nationwide increase in tianeptine exposure calls and calls related to abuse and misuse during 2014–2017. [17]

Recreational use

As a μ-opioid agonist, tianeptine in large doses has high abuse potential. In 2001, Singapore's Ministry of Health restricted tianeptine prescribing to psychiatrists due to its recreational potential. [79]

Between 1989 and 2004, in France 141 cases of recreational use were identified, correlating to an incidence of 1 to 3 cases per 1000 persons treated with tianeptine and 45 between 2006 and 2011. According to Servier, stopping of treatment with tianeptine is difficult, due to the possibility of withdrawal symptoms in a person. The severity of the withdrawal is dependent on the daily dose, with high doses being extremely difficult to quit. [80] [ better source needed ] [81] [82] An official DEA statement [83] states that the withdrawal symptoms in humans typically result in: agitation, nausea, vomiting, tachycardia, hypertension, diarrhea, tremor, and diaphoresis, similar to other opioid drugs.

In 2007, according to French Health Products Safety Agency, tianeptine's manufacturer Servier agreed to modify the drug's label, following problems with dependency. [84]

Tianeptine has been intravenously injected by drug users in Russia. [85] [86] This method of administration reportedly causes an opioid-like effect and is sometimes used in an attempt to lessen opioid withdrawal symptoms. [85] Tianeptine tablets contain silica and do not dissolve completely. Often the solution is not filtered well thus particles in the injected fluid block capillaries, leading to thrombosis and then severe necrosis. Thus, in Russia tianeptine (sold under the brand name "Coaxil") is a schedule III controlled substance in the same list as the majority of benzodiazepines and barbiturates. [87]

The Centers for Disease Control and Prevention (CDC) has expressed concern that tianeptine may be an "emerging public health risk", citing an increase in exposure-related calls to poison control centers in the United States. [17] Sold retail as a dietary supplement and touted as a mood-booster and an aid for concentration, it is colloquially known as "gas-station heroin". [88] In the US, it is an unregulated drug sold under several product names and has been found to be adulterated with synthetic cannabinoid receptor agonists (SCRAs) or other drugs. [20]

A literature review conducted in 2018 found 25 articles involving 65 patients with tianeptine abuse or dependence. [37] Limited data showed that a majority of patients were male and that age ranged from 19 to 67. Routes of intake included oral, intravenous, and insufflation entry. In the 15 cases of overdose, 8 combined ingestion with at least one other substance, of which 3 resulted in death. Six additional deaths are reported involving tianeptine (making it 9 in total). In this report, the amount of tianeptine used ranged from 50 mg/day to 10 g/day orally.

Legality

In 2003, Bahrain classified tianeptine a controlled substance due to increasing reports of misuse and recreational use. [89]

In Russia, tianeptine (sold under the brand name "Coaxil") is a schedule III controlled substance in the same list as the majority of benzodiazepines and barbiturates. [87]

On March 13, 2020, with a decree approved by the Minister of Health, Italy became the first European country to outlaw tianeptine considering it a Class I controlled substance. [90]

In the United States, tianeptine is not considered by the Drug Enforcement Administration as a controlled substance or analogue thereof. [91] However, its use in dietary supplements and food is unlawful. [92] The U.S. F.D.A. has issued warnings, as recently as January 2024, about the dangers of recreational tianeptine use and the risks posed by adulterated dietary supplements containing undeclared tianeptine. [93]

On 6 April 2018 Michigan became the first U.S. state to outlaw tianeptine sodium, classifying it as a schedule II controlled substance. [94] The scheduling of tianeptine sodium is effective 4 July 2018. [95]

On March 15, 2021, Alabama outlawed tianeptine, classifying it as a schedule II controlled substance. [96]

On July 1, 2022, Tennessee outlawed tianeptine and adds "any salt, sulfate, free acid, or other preparation of tianeptine, and any salt, sulfate, free acid, compound, derivative, precursor, or preparation thereof that is substantially chemically equivalent or identical with tianeptine", classifying it as a schedule II controlled substance. [97]

On December 22, 2022, Ohio outlawed tianeptine, classifying it as a schedule I controlled substance with Ohio Governor Mike DeWine referencing the widespread availability of the chemical there as "gas-station heroin." [98]

On March 23, 2023, Kentucky outlawed tianeptine, classifying it as a schedule I substance by an order of the Governor of Kentucky. [99] [100]

On September 20, 2023, Florida outlawed tianeptine, classifying it as a schedule I substance by an administrative edict issued by the Florida Attorney General. [101] [102] [103] [ better source needed ]

See also

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

An anxiolytic is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.

<span class="mw-page-title-main">Tricyclic antidepressant</span> Class of medications

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The effectiveness of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Tramadol</span> Medication of the opioid type, patented 1972

Tramadol, sold under the brand name Ultram among others, is an opioid pain medication and a serotonin–norepinephrine reuptake inhibitor (SNRI) used to treat moderately severe pain. When taken by mouth in an immediate-release formulation, the onset of pain relief usually begins within an hour. It is also available by injection. It is available in combination with paracetamol (acetaminophen).

<span class="mw-page-title-main">Venlafaxine</span> Antidepressant medication

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD). It may also be used for chronic pain. It is taken by mouth. It is also available as the salt venlafaxine besylate in an extended-release formulation.

<span class="mw-page-title-main">Mirtazapine</span> Antidepressant medication

Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression. Its effects may take up to four weeks, but can also manifest as early as one to two weeks. It is often used in cases of depression complicated by anxiety or insomnia. The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants. It is taken by mouth.

<span class="mw-page-title-main">Serotonin–norepinephrine reuptake inhibitor</span> Class of antidepressant medication

Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, social phobia, chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. Off-label uses include treatments for attention-deficit hyperactivity disorder (ADHD), obsessive–compulsive disorder (OCD), and migraine prevention. SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters.

<span class="mw-page-title-main">Azapirone</span> Drug class of psycotropic drugs

Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics. They are commonly used as add-ons to other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

<span class="mw-page-title-main">Pindolol</span> Chemical compound

Pindolol, sold under the brand name Visken among others, is a nonselective beta blocker which is used in the treatment of hypertension. It is also an antagonist of the serotonin 5-HT1A receptor, preferentially blocking inhibitory 5-HT1A autoreceptors, and has been researched as an add-on therapy to various antidepressants, such as clomipramine and the selective serotonin reuptake inhibitors (SSRIs), in the treatment of depression and obsessive-compulsive disorder.

Functional selectivity is the ligand-dependent selectivity for certain signal transduction pathways relative to a reference ligand at the same receptor. Functional selectivity can be present when a receptor has several possible signal transduction pathways. To which degree each pathway is activated thus depends on which ligand binds to the receptor. Functional selectivity, or biased signaling, is most extensively characterized at G protein coupled receptors (GPCRs). A number of biased agonists, such as those at muscarinic M2 receptors tested as analgesics or antiproliferative drugs, or those at opioid receptors that mediate pain, show potential at various receptor families to increase beneficial properties while reducing side effects. For example, pre-clinical studies with G protein biased agonists at the μ-opioid receptor show equivalent efficacy for treating pain with reduced risk for addictive potential and respiratory depression. Studies within the chemokine receptor system also suggest that GPCR biased agonism is physiologically relevant. For example, a beta-arrestin biased agonist of the chemokine receptor CXCR3 induced greater chemotaxis of T cells relative to a G protein biased agonist.

<span class="mw-page-title-main">Trazodone</span> Antidepressant medication

Trazodone, sold under many brand names, is an antidepressant medication. It is used to treat major depressive disorder, anxiety disorders, and insomnia. The medication is taken orally.

<span class="mw-page-title-main">Mianserin</span> Antidepressant

Mianserin, sold under the brand name Tolvon among others, is an atypical antidepressant that is used primarily in the treatment of depression in Europe and elsewhere in the world. It is a tetracyclic antidepressant (TeCA). Mianserin is closely related to mirtazapine, both chemically and in terms of its actions and effects, although there are significant differences between the two drugs.

<span class="mw-page-title-main">Fluoxetine</span> SSRI antidepressant

Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), anxiety, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is also approved for treatment of major depressive disorder in adolescents and children 8 years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth.

A serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of drug that acts as a combined reuptake inhibitor of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. It does this by concomitantly inhibiting the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), respectively. Inhibition of the reuptake of these neurotransmitters increases their extracellular concentrations and, therefore, results in an increase in serotonergic, adrenergic, and dopaminergic neurotransmission. The naturally-occurring and potent SNDRI cocaine is widely used recreationally and often illegally for the euphoric effects it produces.

5-HT<sub>1A</sub> receptor Serotonin receptor protein distributed in the cerebrum and raphe nucleus

The serotonin 1A receptor is a subtype of serotonin receptors, or 5-HT receptors, that binds serotonin, also known as 5-HT, a neurotransmitter. 5-HT1A is expressed in the brain, spleen, and neonatal kidney. It is a G protein-coupled receptor (GPCR), coupled to the Gi protein, and its activation in the brain mediates hyperpolarization and reduction of firing rate of the postsynaptic neuron. In humans, the serotonin 1A receptor is encoded by the HTR1A gene.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

The pharmacology of antidepressants is not entirely clear. The earliest and probably most widely accepted scientific theory of antidepressant action is the monoamine hypothesis, which states that depression is due to an imbalance of the monoamine neurotransmitters. It was originally proposed based on the observation that certain hydrazine anti-tuberculosis agents produce antidepressant effects, which was later linked to their inhibitory effects on monoamine oxidase, the enzyme that catalyses the breakdown of the monoamine neurotransmitters. All currently marketed antidepressants have the monoamine hypothesis as their theoretical basis, with the possible exception of agomelatine which acts on a dual melatonergic-serotonergic pathway. Despite the success of the monoamine hypothesis it has a number of limitations: for one, all monoaminergic antidepressants have a delayed onset of action of at least a week; and secondly, there are a sizeable portion (>40%) of depressed patients that do not adequately respond to monoaminergic antidepressants. Further evidence to the contrary of the monoamine hypothesis are the recent findings that a single intravenous infusion with ketamine, an antagonist of the NMDA receptor — a type of glutamate receptor — produces rapid, robust and sustained antidepressant effects. Monoamine precursor depletion also fails to alter mood. To overcome these flaws with the monoamine hypothesis a number of alternative hypotheses have been proposed, including the glutamate, neurogenic, epigenetic, cortisol hypersecretion and inflammatory hypotheses. Another hypothesis that has been proposed which would explain the delay is the hypothesis that monoamines don't directly influence mood, but influence emotional perception biases.

References

  1. ↑ Uzbekov M (2011). "FC13-09 - Antidepressant tianeptine (TIA) action is based on the acceleration of serotonin turnover in the synapse: a hypothesis". European Psychiatry. 26: 1890. doi:10.1016/S0924-9338(11)73594-5. S2CID   143885547 . Retrieved 3 December 2023.
  2. ↑ Wagner ML, Pergolizzi J, Lequang JA, Breve F, Varrassi G (June 2023). "From Antidepressant Tianeptine to Street Drug ZaZa: A Narrative Review". Cureus. 15 (6): e40688. doi: 10.7759/cureus.40688 . PMC   10359047 . PMID   37485121.
  3. 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1195–. ISBN   978-1-4757-2085-3.
  4. 1 2 Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 1024–. ISBN   978-3-88763-075-1.
  5. 1 2 "Tianeptine (International database)". Drugs.com.
  6. 1 2 3 4 "Tianeptine – AdisInsight". AdisInsight. Springer. Retrieved 31 January 2016.
  7. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  8. ↑ "Poisons Standard June 2017". 29 May 2017.
  9. 1 2 3 4 5 6 Royer RJ, Albin H, Barrucand D, Salvadori-Failler C, Kamoun A (1988). "Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors". Clinical Neuropharmacology. 11 (Suppl 2): S90-6. PMID   3180120.
  10. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Wagstaff AJ, Ormrod D, Spencer CM (March 2001). "Tianeptine: a review of its use in depressive disorders". CNS Drugs. 15 (3): 231–59. doi:10.2165/00023210-200115030-00006. PMID   11463130. S2CID   37796160.
  11. ↑ Fromenty B, Freneaux E, Labbe G, Deschamps D, Larrey D, Letteron P, Pessayre D (1 November 1989). "Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice". Biochem Pharmacol. 38 (21): 3743–3751. doi:10.1016/0006-2952(89)90580-7. PMID   2597170.
  12. 1 2 Carlhant D, Le Garrec J, Guedes Y, Salvadori C, Mottier D, Riche C (September 1990). "Pharmacokinetics and bioavailability of tianeptine in the elderly". Drug Investigation. 2 (3): 167–172. doi:10.1007/BF03259191. S2CID   56502717.
  13. ↑ Defrance R, Marey C, Kamoun A (1988). "Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials" (PDF). Clinical Neuropharmacology. 11 (Suppl 2): S74-82. PMID   2902922. Archived from the original (PDF) on 4 April 2016.
  14. 1 2 3 4 5 6 7 8 Kasper S, McEwen BS (2008). "Neurobiological and clinical effects of the antidepressant tianeptine". CNS Drugs. 22 (1): 15–26. doi:10.2165/00023210-200822010-00002. PMID   18072812. S2CID   30330824.
  15. 1 2 3 4 5 6 7 8 9 10 Gassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D (July 2014). "The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist". Translational Psychiatry. 4 (7): e411. doi:10.1038/tp.2014.30. PMC   4119213 . PMID   25026323.
  16. ↑ Berridge KC, Kringelbach ML (August 2008). "Affective neuroscience of pleasure: reward in humans and animals". Psychopharmacology. 199 (3): 457–80. doi:10.1007/s00213-008-1099-6. PMC   3004012 . PMID   18311558.
  17. 1 2 3 El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, et al. (August 2018). "Characteristics of Tianeptine Exposures Reported to the National Poison Data System - United States, 2000-2017". MMWR. Morbidity and Mortality Weekly Report. 67 (30): 815–818. doi:10.15585/mmwr.mm6730a2. PMC   6072055 . PMID   30070980.
  18. 1 2 3 4 5 6 Akiki T. "The etiology of depression and the therapeutic implications". Glob. J. Med. Res. 13 (6). ISSN   2249-4618. Archived from the original on 3 November 2016. Retrieved 26 August 2015.
  19. ↑ Tianeptine Sodium. London, UK: Pharmaceutical Press. 5 December 2011. Retrieved 2 December 2013.{{cite book}}: |work= ignored (help)
  20. 1 2 Counts CJ (2024). "Notes from the Field: Cluster of Severe Illness from Neptune's Fix Tianeptine Linked to Synthetic Cannabinoids — New Jersey, June–November 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (4): 89–90. doi: 10.15585/mmwr.mm7304a5 . ISSN   0149-2195. PMC   10843069 . PMID   38300852.
  21. ↑ Schruers K, Griez E (December 2004). "The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder". Journal of Psychopharmacology. 18 (4): 553–8. doi:10.1177/0269881104047283. PMID   15582922. S2CID   26981110.
  22. ↑ Baune BT, Renger L (September 2014). "Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression--a systematic review". Psychiatry Research. 219 (1): 25–50. doi:10.1016/j.psychres.2014.05.013. PMID   24863864. S2CID   23684657.
  23. ↑ El-Shafey H, Atteya A, Abu El-Magd S, Hassanein A, Fathy A, Shamloul R (September 2006). "Tianeptine can be effective in men with depression and erectile dysfunction". The Journal of Sexual Medicine. 3 (5): 910–917. doi:10.1111/j.1743-6109.2005.00141.x. PMID   16942535.
  24. ↑ Levin OS (May 2007). "Coaxil (tianeptine) in the treatment of depression in Parkinson's disease". Neuroscience and Behavioral Physiology. 37 (4): 419–24. doi:10.1007/s11055-007-0029-0. PMID   17457538. S2CID   7637174.
  25. ↑ Aleksandrovskiĭ I, Avedisova AS, Boev IV, Bukhanovkskiĭ AO, Voloshin VM, Tsygankov BD, Shamreĭ BK (2005). "[Efficacy and tolerability of coaxil (tianeptine) in the therapy of posttraumatic stress disorder]" Эффективность и переносимость коаксила (тианептина) при терапии посттравматического стрессового расстройства[Efficacy and tolerability of coaxil (tianeptine) in the therapy of posttraumatic stress disorder]. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova (in Russian). 105 (11): 24–9. PMID   16329631.
  26. ↑ Onder E, Tural U, Aker T (April 2006). "A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake". European Psychiatry. 21 (3): 174–9. doi:10.1016/j.eurpsy.2005.03.007. PMID   15964747. S2CID   21322928.
  27. ↑ Sohn W, Lee OY, Kwon JG, Park KS, Lim YJ, Kim TH, et al. (September 2012). "Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study". Neurogastroenterology and Motility. 24 (9): 860–e398. doi:10.1111/j.1365-2982.2012.01945.x. PMID   22679908. S2CID   2914428.
  28. 1 2 3 4 Lechin F, van der Dijs B, Lechin AE (November 2004). "Treatment of bronchial asthma with tianeptine". Methods and Findings in Experimental and Clinical Pharmacology. 26 (9): 697–701. doi:10.1358/mf.2004.26.9.872567. PMID   15632955.
  29. 1 2 Uzbay TI (May 2008). "Tianeptine: potential influences on neuroplasticity and novel pharmacological effects". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (4): 915–24. doi:10.1016/j.pnpbp.2007.08.007. PMID   17826881. S2CID   22365299.
  30. ↑ "ISRCTN16400909 – Tianeptine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study". Controlled-trials.com. Archived from the original on 21 July 2010. Retrieved 13 August 2010.
  31. ↑ Niederhofer H (2004). "Tianeptine as a slightly effective therapeutic option for attention-deficit hyperactivity disorder". Neuropsychobiology. 49 (3): 130–3. doi:10.1159/000076721. PMID   15034228. S2CID   34300575.
  32. ↑ "Package Insert – Stablon (German)" (PDF). Servier Austria GmbH. 20 August 2012. Archived from the original (PDF) on 11 August 2016. Retrieved 24 February 2020.
  33. ↑ Le Bricquir Y, Larrey D, Blanc P, Pageaux GP, Michel H (November 1994). "Tianeptine--an instance of drug-induced hepatotoxicity predicted by prospective experimental studies". Journal of Hepatology. 21 (5): 771–773. doi:10.1016/s0168-8278(94)80237-8. PMID   7890892.
  34. ↑ Voican CS, Corruble E, Naveau S, Perlemuter G (April 2014). "Antidepressant-induced liver injury: a review for clinicians". The American Journal of Psychiatry. 171 (4): 404–15. doi:10.1176/appi.ajp.2013.13050709. PMID   24362450.
  35. ↑ Billioti de Gage S, Collin C, Le-Tri T, Pariente A, Bégaud B, Verdoux H, et al. (July 2018). "Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database". CNS Drugs. 32 (7): 673–684. doi:10.1007/s40263-018-0537-1. PMC   6061298 . PMID   29959758.
  36. ↑ Bril A, Abadie C, Ben Baouali A, Maupoil V, Rochette L (1993). "Absence of relationship between antiarrhythmic effects of antidepressant drugs and lipid peroxidation". Pharmacology. 46 (1): 23–32. doi:10.1159/000139025. PMID   8434029.
  37. 1 2 Lauhan R, Hsu A, Alam A, Beizai K (November 2018). "Tianeptine Abuse and Dependence: Case Report and Literature Review". Psychosomatics. 59 (6): 547–553. doi:10.1016/j.psym.2018.07.006. PMID   30149933. S2CID   52099752.
  38. ↑ Vadachkoria D, Gabunia L, Gambashidze K, Pkhaladze N, Kuridze N (September 2009). "Addictive potential of Tianeptine - the threatening reality". Georgian Medical News (174): 92–4. PMID   19801742.
  39. ↑ Waintraub L, Septien L, Azoulay P (January 2002). "Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine". CNS Drugs. 16 (1): 65–75. doi:10.2165/00023210-200216010-00005. PMID   11772119. S2CID   31125177.
  40. ↑ Gülen Yıldırım S, Başterzi AD, Göka E (2004). "Tianeptinin Neden Olduğu Hipomani; Bir Olgu Sunumu" [Tianeptine Induced Mania: A Case Report](PDF). Klinik Psikiyatri Dergisi (in Turkish). 7 (4): 177–180. Archived from the original (PDF) on 30 June 2006.
  41. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  42. 1 2 3 4 5 6 Samuels BA, Nautiyal KM, Kruegel AC, Levinstein MR, Magalong VM, Gassaway MM, et al. (September 2017). "The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor". Neuropsychopharmacology. 42 (10): 2052–2063. doi:10.1038/npp.2017.60. PMC   5561344 . PMID   28303899.
  43. ↑ Springer J, Cubała WJ (March 2018). "Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature". Journal of Psychoactive Drugs. 50 (3): 275–280. doi:10.1080/02791072.2018.1438687. PMID   29494783. S2CID   3603781.
  44. ↑ Marraffa JM, Stork CM, Hoffman RS, Su MK (November 2018). "Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuse". Clinical Toxicology. 56 (11): 1155–1158. doi:10.1080/15563650.2018.1476694. PMID   29799284. S2CID   44112801.
  45. ↑ Cavalla D, Chianelli F, Korsak A, Hosford PS, Gourine AV, Marina N (August 2015). "Tianeptine prevents respiratory depression without affecting analgesic effect of opiates in conscious rats". European Journal of Pharmacology. 761: 268–72. doi:10.1016/j.ejphar.2015.05.067. PMID   26068549.
  46. ↑ Algera H, van der Schrier R, Cavalla D, van Velzen M, Roozekrans M, McMorn A, et al. (October 2022). "Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression". Anesthesiology. 137 (4): 446–458. doi: 10.1097/ALN.0000000000004324 . PMID   35867853. S2CID   250989511.
  47. 1 2 3 4 5 6 McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E (March 2010). "The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation". Molecular Psychiatry. 15 (3): 237–49. doi:10.1038/mp.2009.80. PMC   2902200 . PMID   19704408.
  48. 1 2 McEwen BS, Chattarji S (December 2004). "Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine". European Neuropsychopharmacology. 14 (Suppl 5): S497-502. doi:10.1016/j.euroneuro.2004.09.008. PMID   15550348. S2CID   21953270.
  49. 1 2 McEwen BS, Olié JP (June 2005). "Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine". Molecular Psychiatry. 10 (6): 525–37. doi: 10.1038/sj.mp.4001648 . PMID   15753957.
  50. 1 2 Brink CB, Harvey BH, Brand L (January 2006). "Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression". Recent Patents on CNS Drug Discovery. 1 (1): 29–41. doi:10.2174/157488906775245327. PMID   18221189. Archived from the original on 14 April 2013.
  51. 1 2 3 4 5 Bailey SJ, Almatroudi A, Kouris A (2018). "Tianeptine: An Atypical Antidepressant with Multimodal Pharmacology" (PDF). Current Psychopharmacology. 6 (2). doi:10.2174/2211556006666170525154616. ISSN   2211-5560. S2CID   55965184.
  52. ↑ Mennini T, Mocaer E, Garattini S (November 1987). "Tianeptine, a selective enhancer of serotonin uptake in rat brain". Naunyn-Schmiedeberg's Archives of Pharmacology. 336 (5): 478–82. doi:10.1007/bf00169302. PMID   3437921. S2CID   21499462.
  53. ↑ Oluyomi AO, Datla KP, Curzon G (March 1997). "Effects of the (+) and (-) enantiomers of the antidepressant drug tianeptine on 5-HTP-induced behaviour". Neuropharmacology. 36 (3): 383–7. doi:10.1016/s0028-3908(97)00016-6. PMID   9175617. S2CID   11465294.
  54. ↑ Alici T, Kayir H, Aygoren MO, Saglam E, Uzbay IT (January 2006). "Discriminative stimulus properties of tianeptine". Psychopharmacology. 183 (4): 446–51. doi:10.1007/s00213-005-0210-5. PMID   16292591. S2CID   5820336.
  55. ↑ Invernizzi R, Pozzi L, Garattini S, Samanin R (March 1992). "Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism". Neuropharmacology. 31 (3): 221–7. doi:10.1016/0028-3908(92)90171-K. PMID   1630590. S2CID   21610131.
  56. ↑ Dziedzicka-Wasylewska M, Rogoz Z, Skuza G, Dlaboga D, Maj J (March 2002). "Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2) /D(3) receptors". Behavioural Pharmacology. 13 (2): 127–38. doi:10.1097/00008877-200203000-00004. PMID   11981225. S2CID   2126834.
  57. ↑ Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ (October 1994). "Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein". Cell. 79 (1): 59–68. doi:10.1016/0092-8674(94)90400-6. PMID   7923378. S2CID   17250247.
  58. ↑ Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, McNamara JO, White LE (2008). Neuroscience (4th ed.). Sinauer Associates. pp.  170–6. ISBN   978-0-87893-697-7.
  59. ↑ Douglass J, Daoud S (March 1996). "Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript". Gene. 169 (2): 241–5. doi:10.1016/0378-1119(96)88651-3. PMID   8647455.
  60. ↑ Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, et al. (May 1998). "Hypothalamic CART is a new anorectic peptide regulated by leptin". Nature. 393 (6680): 72–6. Bibcode:1998Natur.393...72K. doi:10.1038/29993. PMID   9590691. S2CID   4427258.
  61. ↑ Zhang M, Han L, Xu Y (June 2012). "Roles of cocaine- and amphetamine-regulated transcript in the central nervous system". Clinical and Experimental Pharmacology & Physiology. 39 (6): 586–92. doi:10.1111/j.1440-1681.2011.05642.x. PMID   22077697. S2CID   25134612.
  62. ↑ Kuhar MJ, Adams S, Dominguez G, Jaworski J, Balkan B (February 2002). "CART peptides". Neuropeptides. 36 (1): 1–8. doi:10.1054/npep.2002.0887. PMID   12147208. S2CID   7079530.
  63. ↑ Rogge GA, Jones DC, Green T, Nestler E, Kuhar MJ (January 2009). "Regulation of CART peptide expression by CREB in the rat nucleus accumbens in vivo". Brain Research. 1251: 42–52. doi:10.1016/j.brainres.2008.11.011. PMC   2734444 . PMID   19046951.
  64. 1 2 Zhao WN, Ghosh B, Tyler M, Lalonde J, Joseph NF, Kosaric N, et al. (September 2018). "Class I Histone Deacetylase Inhibition by Tianeptinaline Modulates Neuroplasticity and Enhances Memory". ACS Chemical Neuroscience. 9 (9): 2262–2273. doi:10.1021/acschemneuro.8b00116. hdl:1721.1/126372. PMID   29932631. S2CID   49389560.
  65. ↑ "Tianeptine sulfate salt forms and methods of making and using the same".
  66. ↑ "Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder". Tonix Pharmaceuticals Holding Corp. GlobeNewswire News Room. 3 October 2022. Retrieved 5 November 2022.
  67. ↑ Szafarz M, Wencel A, Pociecha K, Fedak FA, Wlaź P, Wyska E (February 2018). "Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method". Naunyn-Schmiedeberg's Archives of Pharmacology. 391 (2): 185–196. doi:10.1007/s00210-017-1448-2. PMC   5778159 . PMID   29230490. S2CID   253742631.
  68. ↑ FR 2104728,Malen C, Danrée B, Poignant JC,"Nouveaux dérivés tricycliques et leur procédé de préparation [Novel tricyclic derivatives and process for preparing the same]",published 1972-04-21, assigned to Science Union et CIE Societe Francaise de Recherche Medicale
  69. ↑ Kruegel AC (2015). Chemical and Biological Explorations of Novel Opioid Receptor Modulators (Thesis). Columbia University. p. 338-358. doi:10.7916/d8v1242f.
  70. ↑ Labrid C, Moleyre J, Poignant JC, Malen C, Mocaër E, Kamoun A (1988). "Structure-activity relationships of tricyclic antidepressants, with special reference to tianeptine". Clinical Neuropharmacology. 11 (Suppl 2): S21–S31. PMID   3180115.
  71. ↑ Sánchez-Mateo CC, Darias V, Expósito-Orta MA, Albertos LM (January 2003). "Neuropharmacological study of hetero[2,1]benzothiazepine derivatives analogues of tianeptine". Farmaco. 58 (1). Societa Chimica Italiana: 1–10. doi:10.1016/S0014-827X(02)00021-6. PMID   12595031.
  72. ↑ Sánchez-Mateo CC, Darias V, Albertos LM, Expósito-Orta MA (2003). "Psychopharmacological effects of tianeptine analogous hetero[2,1] benzothiazepine derivatives". Arzneimittel-Forschung. 53 (1): 12–20. doi:10.1055/s-0031-1297064. PMID   12608009. S2CID   23593291.
  73. ↑ Expósito-Orta MA, Albertos LM, Darias V, Sánchez-Mateo CC (2004). "Behavioural effects of thieno and pyrazolo [2,1] benzothiazepine derivatives in mice". Arzneimittel-Forschung. 54 (7): 365–70. doi:10.1055/s-0031-1296985. PMID   15344839. S2CID   24437547.
  74. ↑ Kruegel AC (2015). Chemical and Biological Explorations of Novel Opioid Receptor Modulators (PhD thesis). Columbia University. doi:10.7916/D8V1242F.
  75. ↑ US 10183919,Kruegel AC, Henke A, Gassaway MM, Rives MM, Javitch JA, Sames D,"Class of mu-opioid receptor agonists",published 2019-01-22, assigned to The Trustees of Columbia University in the City of New York
  76. ↑ WO 2017049158,Kruegel A, Sames D, Gassaway M, Javitch JA,"Carboxylic diarylthiazepineamines as mu-opioid receptor agonists",published 2017-03-23, assigned to The Trustees of Columbia University in the City of New York
  77. ↑ "Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder". Tonix Pharmaceuticals Holding Corp. 31 October 2023. Retrieved 2 November 2023.
  78. ↑ Javitch JA (15 June 2023). "Tianeptine for Treatment Resistant Depression". Clinicaltrials.gov. Retrieved 2 November 2023.
  79. ↑ World Health Organization (2001). "Pharmaceuticals: Restrictions in use and availability, March 2001" (PDF). Archived from the original (PDF) on 17 November 2008. Retrieved 24 July 2008.
  80. ↑ APM Health Europe (2007). "Addiction leads to warning on Servier's antidepressant Stablon". Archived from the original on 7 July 2011. Retrieved 24 July 2008.
  81. ↑ Gibaja V (2006). "Use, Drug Abuse and Tianeptine (in French)" (PDF). Archived from the original (PDF) on 20 July 2011. Retrieved 24 July 2008.
  82. ↑ "Tianeptine (Stablon°) dans la dépression : risque trop important de dépendance". www.prescrire.org.
  83. ↑ "Drug Enforcement AdministrationDiversion Control DivisionDrug & Chemical Evaluation Section - Tianeptine" (PDF).
  84. ↑ French Health Products Safety Agency (Afssaps) (2007). "Important Information on Drug: Update of the Summary of Product Characteristics Stablon, 16 May 2007 (French)". Archived from the original on 1 April 2008. Retrieved 24 July 2008.
  85. 1 2 Ives R (2008). "Assessment Mission Report for the SCAD V Programme, Component on Prevention and on Media Work" (PDF). Archived from the original (PDF) on 1 December 2010. Retrieved 4 November 2008.
  86. ↑ "Illicit Drug Trades in the Russian Federation" (PDF). United Nations Office on Drugs and Crime. April 2008. Retrieved 16 July 2014.
  87. 1 2 "Decision of the Government of the Russian Federation No. 681 of June 30, 1998 on the Approval of the List of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (with Amendments and Additions)" (in Russian).
  88. ↑ Hoffman J (10 January 2024). "'Gas-Station Heroin' Sold as Dietary Supplement Alarms Health Officials". The New York Times– via NYTimes.com.
  89. ↑ World Health Organization (2003). "Pharmaceuticals: Restrictions in use and availability, April 2003" (PDF). Archived from the original (PDF) on 29 June 2011. Retrieved 24 July 2008.
  90. ↑ "Gazzetta Ufficiale".
  91. ↑ "Tianeptine" (PDF). Office of Diversion Control at the D.E.A. Retrieved 25 May 2023.
  92. ↑ "Tianeptine in Dietary Supplements". Food and Drug Administration. 22 February 2023. Retrieved 25 May 2023.
  93. ↑ Musa A (24 January 2024). "FDA urges consumers not to buy tianeptine products due to serious risks as lawmakers call for "immediate action"". CNN. Retrieved 30 January 2024.
  94. ↑ "Michigan approves ban on antidepressant tianeptine sodium". Associated Press – via Detroit Free Press.
  95. ↑ "Public Health Code Section 333.7214.amended". Michigan Legislature. Legislative Council, State of Michigan. Retrieved 18 May 2018.[ permanent dead link ]
  96. ↑ "New crime trend in Giles Co. after Alabama stops selling ZaZa Red, controversial stimulant". WKRN News 2. 25 May 2021. Retrieved 14 December 2022.
  97. ↑ "HB 2043 by Cochran: Controlled Substances". Tennessee General Assembly. 30 March 2022. Archived from the original on 8 April 2022.
  98. ↑ "Governor DeWine Authorizes the State of Ohio Board of Pharmacy to Adopt Emergency Rule to Ban the Sale and Use of Tianeptine" (PDF). State of Ohio Board of Pharmacy. 23 December 2022. Retrieved 5 January 2023.
  99. ↑ https://governor.ky.gov/attachments/20230323_902-KAR-55-015E.pdf
  100. ↑ "Growing Danger Of 'Gas Station Heroin': Kentucky Latest State To Ban Tianeptine—Opioid-Like Drug Sold In Groceries". Forbes. Retrieved 26 October 2023.
  101. ↑ https://www.myfloridalegal.com/sites/default/files/2023-09/2er23-1.pdf
  102. ↑ "VIDEO: Attorney General Moody Outlaws Gas Station Heroin in Florida | My Florida Legal".
  103. ↑ "Florida Just Banned 'Gas Station Heroin'". 25 September 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.